Announcement on Subsidiary SYS6041 Obtaining Drug Clinical Trial Approval Notice

CSPC Innovation Pharmaceutical Co., Ltd.·June 15, 2026·2 pages

✨ AI Summary

Stone Innovative Pharmaceutical's subsidiary received a clinical trial approval notice for SYS6041, an antibody-drug conjugate targeting FRα. The approval allows for clinical trials in combination therapy for ovarian cancer. This expands SYS6041's application scope, with Phase I trials showing competitiveness. The company anticipates potential risks in drug development and market launch.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300765

Stock Abbreviation: Xin Nuo Wei

Announcement No.: 2026-050

Stone Innovative Pharmaceutical Co., Ltd.

Announcement on Subsidiary SYS6041 Obtaining Drug Clinical Trial Approval Notice

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

I. Overview

Stone Innovative Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company")'s holding subsidiary, Shijie Group Giant Stone Biopharmaceutical Co., Ltd. (hereinafter referred to as "Giant Stone Biopharmaceutical"), recently received the "Drug Clinical Trial Approval Notice" for SYS6041 (Folic Acid Receptor ADC) issued by the National Medical Products Administration, and will commence clinical trials in the near future. The relevant situation is hereby announced as follows:

II. Basic Drug Information

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.